All In Biotech

Drug Trial Radar · NCT06413095

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Pembrolizumab Alone and in Combination(s) With MK-0482 and MK-4830 Via Intratumoral Injection in Patients With Head and Neck Squamous Cell Carcinoma or Soft Tissue Sarcoma Prior to Planned Surgical Intervention

Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Jun 1, 2022

Primary completion

Jun 22, 2023

Study completion Jun 22, 2023

Sponsor

Lead sponsor
Presage BiosciencesIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
May 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, Phase 0 substudy designed to evaluate the ability of pembrolizumab, alone and in combination with MK-0482 or MK-4830, to elicit pharmacodynamic changes suggestive of antitumor immune activation within the native tumor microenvironment (TME) following intratumoral microdosing via the CIVO device in patients with surface accessible Head and Neck Squamous Cell Carcinoma (HNSCC) or Soft Tissue Sarcoma (STS) lesion(s) who are scheduled for tumor and/or regional node dissection as part of their standard treatment.

Conditions

  • Head and Neck Squamous Cell Carcinoma
  • Soft Tissue Sarcoma

Interventions

  • PembrolizumabBiological

    Intratumoral microdose injection by the CIVO device.

  • MK-0482 + PembrolizumabCombination product

    Intratumoral microdose injection by the CIVO device.

  • MK-4830 + PembrolizumabCombination product

    Intratumoral microdose injection by the CIVO device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quantification of Immune Cell Biomarkers by Immunohistochemistry (IHC), In Situ Hybridization (ISH), and/or Spatial Biology PlatformsTime frame: 2 to 4 days after microdose injection

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • UC Davis

    Sacramento, California

  • Emory Winship Cancer Institute

    Atlanta, Georgia

  • LSU Health Sciences Center - Shreveport

    Shreveport, Louisiana

  • Montefiore Medical Center

    The Bronx, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • UC Health

    Cincinnati, Ohio

  • Oregon Health & Science University (OHSU)

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Sarah Cannon Medical Center

    Charleston, South Carolina

  • UT Health Houston

    Houston, Texas

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.